These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20332253)

  • 1. Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles.
    Shebl FM; Pinto LA; García-Piñeres A; Lempicki R; Williams M; Harro C; Hildesheim A
    Cancer Epidemiol Biomarkers Prev; 2010 Apr; 19(4):978-81. PubMed ID: 20332253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.
    García-Piñeres A; Hildesheim A; Dodd L; Kemp TJ; Williams M; Harro C; Lowy DR; Schiller JT; Pinto LA
    Clin Vaccine Immunol; 2007 Aug; 14(8):984-9. PubMed ID: 17596432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood.
    Pinto LA; Castle PE; Roden RB; Harro CD; Lowy DR; Schiller JT; Wallace D; Williams M; Kopp W; Frazer IH; Berzofsky JA; Hildesheim A
    Vaccine; 2005 May; 23(27):3555-64. PubMed ID: 15855014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients.
    García-Piñeres AJ; Hildesheim A; Dodd L; Kemp TJ; Yang J; Fullmer B; Harro C; Lowy DR; Lempicki RA; Pinto LA
    J Immunol; 2009 Feb; 182(3):1706-29. PubMed ID: 19155521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer.
    Echchannaoui H; Bianchi M; Baud D; Bobst M; Stehle JC; Nardelli-Haefliger D
    Infect Immun; 2008 May; 76(5):1940-51. PubMed ID: 18332214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production and Preliminary In Vivo Evaluations of a Novel in silico-designed L2-based Potential HPV Vaccine.
    Negahdaripour M; Nezafat N; Heidari R; Erfani N; Hajighahramani N; Ghoshoon MB; Shoolian E; Rahbar MR; Najafipour S; Dehshahri A; Morowvat MH; Ghasemi Y
    Curr Pharm Biotechnol; 2020; 21(4):316-324. PubMed ID: 31729940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.
    Chen Y; Liu Y; Zhang G; Wang A; Dong Z; Qi Y; Wang J; Zhao B; Li N; Jiang M
    Virus Res; 2016 Jul; 220():97-103. PubMed ID: 27107614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An effective DNA priming-protein boosting approach for the cervical cancer vaccination.
    Kianmehr Z; Ardestani SK; Soleimanjahi H; Farahmand B; Abdoli A; Khatami M; Akbari K; Fotouhi F
    Pathog Dis; 2015 Mar; 73(2):1-8. PubMed ID: 25722486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.
    Yan X; Wang D; Liang F; Fu L; Guo C
    Hum Vaccin Immunother; 2014; 10(12):3491-8. PubMed ID: 25483698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Papillomavirus Vaccine-Induced Cytokine Messenger RNA Expression in Vaccinated Women.
    Gonçalves AK; Giraldo PC; Machado PR; Farias KJ; Costa AP; Freitas JC; Eleutério J; Witkin SS
    Viral Immunol; 2015; 28(6):339-42. PubMed ID: 25965646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
    Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
    Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
    J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
    Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
    Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody.
    Liu DW; Chang JL; Tsao YP; Huang CW; Kuo SW; Chen SL
    Int J Cancer; 2005 Jan; 113(1):93-100. PubMed ID: 15386434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA; Viscidi R; Harro CD; Kemp TJ; García-Piñeres AJ; Trivett M; Demuth F; Lowy DR; Schiller JT; Berzofsky JA; Hildesheim A
    Virology; 2006 Sep; 353(2):451-62. PubMed ID: 16863657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency.
    Oumeslakht L; Ababou M; Badaoui B; Qmichou Z
    Gene; 2021 May; 782():145533. PubMed ID: 33636291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of human papilloma virus L1 virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activation.
    de Witte L; Zoughlami Y; Aengeneyndt B; David G; van Kooyk Y; Gissmann L; Geijtenbeek TB
    Immunobiology; 2007; 212(9-10):679-91. PubMed ID: 18086370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus-like particles vaccine efficiently produced in a non-fermentative system based on insect larva.
    Millán AF; Gómez-Sebastián S; Nuñez MC; Veramendi J; Escribano JM
    Protein Expr Purif; 2010 Nov; 74(1):1-8. PubMed ID: 20600940
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.